This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 30, 2012 /PRNewswire/ -- Icon plc (NASDAQ: ICLR:
$24) has been picked by S&P Capital IQ as its Focus Stock of the Week. ICLR's American depositary shares (ADSs) carry S&P Capital IQ's highest investment recommendation of 5-STARS, or Strong Buy. ICLR is a leading global contract research organization (CRO) providing outsourced clinical research and development services to the pharmaceutical, biotechnology, and medical devices industries.
"Large pharmaceutical companies are continually seeking to drive efficiencies in their drug development processes to reduce costs associated with the development of new drug candidates and accelerate time to market," said
Jeffrey Loo, equity analyst at S&P Capital IQ. "This has resulted in pharmaceutical firms increasingly outsourcing various research and development functions to CROs, and we believe the main beneficiaries are the larger global CROs such as ICLR."
To view a video of Mr. Loo discussing ICLR click on the following link.
Weblink to videoAbout S&P Capital IQ S&P Capital IQ, a business line of the McGraw-Hill Companies (NYSE: MHP), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Market Intelligence, and company and fund research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit